Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announced that it will host a virtual Key Opinion Leader (KOL) event focused on BNC210 and the treatment of agitation in elderly patients, on Monday, September 10, 2018 at 8:30 a.m. ET.
The event will feature a keynote presentation from:
- • Paul B. Rosenberg, M.D., Professor of Psychiatry and Behavioral Sciences; Johns Hopkins University School of Medicine; Associate Director, Memory and Alzheimer’s Treatment Center Division of Geriatric Psychiatry and Neuropsychiatry; Johns Hopkins University School of Medicine
Bionomics’ management will also provide an overview of the Company’s recent pipeline progress, including its ongoing Phase 2 study of BNC210 in PTSD. In addition, the conference call will feature a fireside chat discussion chaired by H.C. Wainwright Managing Director Joe Pantginis, Ph.D.
In order to participate in the conference call, please dial 866-866-1333 if calling within the US and +1-866-866-1333 if calling outside the US and refer to confirmation number 47442178. A live audio webcast can be accessed on the Bionomics website,www.bionomics.com.au.An archived replay will be available for 30 days after the live event concludes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.